Thomas Povsic, MD, PhD

Articles by Thomas Povsic, MD, PhD

Thomas Povsic, MD, PhD, on Ongoing Research With XC001 Angina Gene Therapy

October 8th 2023

The interventional cardiologist and professor, Duke University School of Medicine, discussed other populations that may benefit from XC001 and the challenges and opportunities with a surgical delivery of treatment.

$Thomas Povsic, MD, PhD, on Addressing Unmet Needs in Refractory Angina With Gene Therapy$

Thomas Povsic, MD, PhD, on Addressing Unmet Needs in Refractory Angina With Gene Therapy

ByThomas Povsic, MD, PhD

August 25th 2023

The interventional cardiologist and professor, Duke University School of Medicine, discussed how XC001 could improve outcomes for patients with refractory angina.

$Thomas Povsic, MD, PhD, on EXACT Clinical Trial: Investigating Gene Therapy for Refractory Angina$

Thomas Povsic, MD, PhD, on EXACT Clinical Trial: Investigating Gene Therapy for Refractory Angina

ByThomas Povsic, MD, PhD

July 26th 2023

The interventional cardiologist and professor, Duke University School of Medicine, discussed trends of new data on XC001.

Thomas Povsic, MD, PhD

Articles by Thomas Povsic, MD, PhD

Thomas Povsic, MD, PhD, on Ongoing Research With XC001 Angina Gene Therapy

Thomas Povsic, MD, PhD, on Addressing Unmet Needs in Refractory Angina With Gene Therapy

Thomas Povsic, MD, PhD, on EXACT Clinical Trial: Investigating Gene Therapy for Refractory Angina

Latest Updated Articles

Trending on CGTlive®

Krystal Biotech’s Neurotrophic Keratitis Gene Therapy Viral Vector Secures FDA Platform Technology Designation

FDA Picks Abeona’s XLRS Gene Therapy ABO-503 for RDEA Pilot Program

Around the Helix: Cell and Gene Therapy Company Updates – October 15, 2025

Tr1X's Multiple Sclerosis Cell Therapy TRX319 Cleared for US Trial

BLA for Rocket’s LAD-I Gene Therapy Under Review by FDA Again